Name | 3-[4-(Piperidin-1-Ylmethyl)phenyl]-9h-Pyrrolo[2,3-B:5,4-C']dipyridine-6-Carbonitrile |
---|---|
Synonyms |
3-[4-(Piperidin-1-Ylmethyl)phenyl]-9h-Pyrrolo[2,3-B:5,4-C']dipyridine-6-Carbonitrile
9H-Pyrrolo[2,3-b:5,4-c']dipyridine-6-carbonitrile, 3-[4-(1-piperidinylmethyl)phenyl]- 3-[4-(1-Piperidinylmethyl)phenyl]-9H-pyrido[4',3':4,5]pyrrolo[2,3-b]pyridine-6-carbonitrile GNE-900 |
Description | GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 µM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. gemcitabine (HY-17026) and GNE-900 administration shows anti-tumor activity[1]. |
---|---|
Related Catalog | |
Target |
Chk1:0.0011 μM (IC50) Chk2:1.5 μM (IC50) |
In Vitro | GNE-900 (1 µM; 1-48 h) 在 HT-29 细胞中与吉西他滨 (50 nM) 联合使用时,可诱导细胞凋亡并增加裂解的 PARP 的表达[1]。 Apoptosis Analysis[1] Cell Line: HT-29 cells Concentration: 1 µM Incubation Time: 1-48 h Result: Inducesd apoptosis with increased the expression of cleaved PARP when combination with gemcitabine (50 nM). |
In Vivo | GNE-900 (2.5-40 mg/kg; p.o.; once) 与gemcitabine (HY-17026) 联用能降低肿瘤体积并增加 DNA 损伤和 γ-H2AX 的表达水平在大鼠中[1]。 Animal Model: Sprague-Dawley rats (HT-29 tumor xenografts)[1] Dosage: 2.5-40 mg/kg (received a dose of gemcitabine 120 mg/kg) Administration: P.o.; once Result: Decreased the tumor volume and resulted in significant enhancement of DNA damage, increased γ-H2AX levels. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 633.4±55.0 °C at 760 mmHg |
Molecular Formula | C23H21N5 |
Molecular Weight | 367.446 |
Flash Point | 336.9±31.5 °C |
Exact Mass | 367.179688 |
LogP | 4.44 |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.727 |